Control Study of Effect of Huanghua Ningshen Granule and Escitalopram on the Treatment of Depression

Objective: To compare the effect and security of Huanghua Ningshen Granule and Escitalopram on the Treatment of Depression. Methods: 120 cases of patients with depression were selected and randomly divided into four groups, with 30 cases in each group. Four groups were given high, middle, and low dosage of Huanghua Ningshen granule and Escitalopram (control group) for 6 weeks. HAMD depression inventory was used to evaluate the effect before treatment, 1 week, 2, 4, and 6 weeks after treatment. TESS was used to evaluate the adverse effect and security index. Results: 120 cases in total completed the research, with 30 cases in each group. The effect rate of all groups were 83.33% vs 86.67%, with P=0.413, and cure rate were 22.22% vs 26.67%, with P=0.35. The difference was not statistically significant, with P>0.05. So did HAMD scores in each time points. The adverse reaction rates of experiment groups and control groups were low and showed no significant statistical difference, with P>0.05. For TESS, the adverse reaction in the Huanghua Ningshen granule group was less. Conclusion: For mild-to-moderate depression, Huanghua Ningshen granule shows better effect than Escitalopram. For severe depression, Escitalopram shows better effect than Huanghua Ningshen granule. At the same time, the side effects of Huanghua Ningshen granule is less than Escitalopram. What's more, it also features high security, good compliance, and low economic burden.